

# Ines Pires da Silva

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8876028/ines-pires-da-silva-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

722  
citations

10  
h-index

17  
g-index

17  
ext. papers

1,068  
ext. citations

7.8  
avg, IF

3.62  
L-index

#	Paper	IF	Citations
14	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101701	2.2	2
13	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
12	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 8-15	7.5	
11	Understanding the Tumour Immune Microenvironment (TIME) at different sites of MELANOMA Metastases (METS). <i>Pathology</i> , <b>2020</b> , 52, S118	1.6	
10	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10005-10005	2.2	17
9	Comprehensive analysis of cutaneous and uveal melanoma liver metastases <b>2020</b> , 8,		16
8	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , <b>2020</b> , 126, 86-97	6.4	54
7	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , <b>2019</b> , 32, 553-563	4.5	20
6	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , <b>2019</b> , 35, 238-255.e6	24.3	230
5	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3247-3258	12.9	15
4	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K -Mutant Melanoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1272-1279	12.9	32
3	Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. <i>Cancer</i> , <b>2015</b> , 121, 51-9	6.4	79
2	Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 410-22	12.5	236
1	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. <i>Journal of Translational Medicine</i> , <b>2014</b> , 12, 342	8.5	16